Adverts

Open Access Articles- Top Results for Basimglurant

Basimglurant

</th></tr>
Basimglurant
File:Basimglurant.svg
Systematic (IUPAC) name
2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine
Clinical data
Identifiers
802906-73-6
None
PubChem CID 11438771
ChemSpider 9613635
Chemical data
Formula C18H13ClFN3
325.767 g/mol

Basimglurant (INN) (code names RG-7090, RO4917523) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche for the treatment of treatment-resistant depression (as an adjunct) and fragile X syndrome.[1][2] As of August 2014, it is in phase II clinical trials for both of these indications.[1][2]

See also

References

  1. ^ a b "Roche - Pipeline". 2014. Retrieved 2014-08-01. 
  2. ^ a b "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.